Meenks SD - Search Results

1

Population pharmacokinetics of unbound ceftriaxone in a critically ill population.

Meenks SD, le Noble JLML, Foudraine NA, de Vries F, Neef K, Janssen PKC. Meenks SD, et al. Int J Clin Pharmacol Ther. 2022 Sep;60(9):373-383. doi: 10.5414/CP204181. Int J Clin Pharmacol Ther. 2022. PMID: 35861497

2

Liquid Chromatography-Tandem Mass Spectrometry to Monitor Unbound and Total Ceftriaxone in Serum of Critically Ill Patients.

Meenks S, le Noble J, Foudraine N, de Vries F, Janssen P. Meenks S, et al. Curr Rev Clin Exp Pharmacol. 2021;16(4):341-349. doi: 10.2174/1574884715666201228115150. Curr Rev Clin Exp Pharmacol. 2021. PMID: 33371859

3

Pharmacokinetics and dose individualization of ceftriaxone in a hepatically-impaired, critically-ill patient receiving continuous venovenous hemofiltration.

Meenks SD, Foudraine NA, Janssen PKC, le Noble JLML. Meenks SD, et al. Int J Clin Pharmacol Ther. 2018 Mar;56(3):148-150. doi: 10.5414/CP203149. Int J Clin Pharmacol Ther. 2018. PMID: 29336776 No abstract available.

4

Ceftriaxone Dosing in a Critically Ill Patient With Hypoalbuminemia During Continuous Venous Hemofiltration: Emphasis on Unbound Pharmacokinetics.

Ebisch RMF, Meenks SD, Foudraine N, Janssen PKC, le Noble JLML. Ebisch RMF, et al. Among authors: meenks sd. J Clin Pharmacol. 2020 Jan;60(1):140-142. doi: 10.1002/jcph.1503. Epub 2019 Aug 13. J Clin Pharmacol. 2020. PMID: 31407809 No abstract available.

5

No effect of norepinephrine dose on anti-Xa activity in critically ill patients .

Meenks SD, Foudraine NA, Broen K, le Noble JLML, Janssen PKC. Meenks SD, et al. Int J Clin Pharmacol Ther. 2020 Apr;58(4):223-229. doi: 10.5414/CP203640. Int J Clin Pharmacol Ther. 2020. PMID: 32000886

6

Quantification of total and unbound cefuroxime in plasma by ultra-performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure.

van Raaij JJ, Mabelis NJD, Shudofsky KN, Meenks SD, le Noble JLML, Janssen PKC. van Raaij JJ, et al. Among authors: meenks sd. J Clin Lab Anal. 2020 Mar;34(3):e23100. doi: 10.1002/jcla.23100. Epub 2019 Nov 30. J Clin Lab Anal. 2020. PMID: 31785116 Free PMC article.

7

Alterations in transmembrane pressures during continuous venovenous haemofiltration significantly contribute to the pharmacokinetic variability of meropenem: a case series of three patients.

le Noble JLML, Meenks SD, Foudraine N, Janssen PKC. le Noble JLML, et al. Among authors: meenks sd. J Antimicrob Chemother. 2019 Jan 1;74(1):271-273. doi: 10.1093/jac/dky411. J Antimicrob Chemother. 2019. PMID: 30295774 No abstract available.

8

Use of serotonergic drugs and the risk of bleeding.

Verdel BM, Souverein PC, Meenks SD, Heerdink ER, Leufkens HG, Egberts TC. Verdel BM, et al. Among authors: meenks sd. Clin Pharmacol Ther. 2011 Jan;89(1):89-96. doi: 10.1038/clpt.2010.240. Epub 2010 Nov 24. Clin Pharmacol Ther. 2011. PMID: 21107313

9

Extremely high unbound flucloxacillin concentrations in a patient with acute septic renal failure during continuous venovenous hemofiltration: Therapeutic drug monitoring to optimize treatment.

Appelman EM, Wammes van-der-Heijden EA, Meenks SD, Janssen PKC, le Noble JLML. Appelman EM, et al. Among authors: meenks sd. Int J Clin Pharmacol Ther. 2023 Mar 5. doi: 10.5414/CP204313. Online ahead of print. Int J Clin Pharmacol Ther. 2023. PMID: 36871242

10

Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study.

Meenks SD, Punt N, le Noble JLML, Foudraine NA, Neef K, Janssen PKC. Meenks SD, et al. Crit Care. 2023 Mar 3;27(1):82. doi: 10.1186/s13054-023-04353-5. Crit Care. 2023. PMID: 36869388 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10 results

Search Page